NMN vs NR: A Deep Dive Into the Pharmacokinetics

NMN vs NR: Pharmacokinetic Deep Dive is not a debate about which molecule is "better" in the abstract. It is a question about what actually reaches your bloodstream, how fast it gets there, and whether that translates into meaningful NAD+ elevation in human tissues. Despite years of marketing claims, the pharmacokinetic data in humans remains sparse, and the two precursors behave differently at the gut wall, in the liver, and in peripheral tissues. This article examines the evidence we have, the gaps we still face, and what it means for anyone considering NAD+ supplementation.

The Evidence Base

The human clinical literature on NMN pharmacokinetics consists of a small number of controlled trials, mostly in East Asian populations, with modest sample sizes and short durations. NR has a slightly larger body of work, but direct head-to-head pharmacokinetic comparisons in humans are essentially nonexistent. What we know comes from separate studies of each compound, often using different dosing protocols, analytical methods, and participant demographics.

Among the NMN trials, Yoshino et al. (2021) conducted a randomized, placebo-controlled, crossover trial in 25 postmenopausal women with prediabetes. Participants received 250 mg NMN daily for 10 weeks. The study measured muscle insulin sensitivity as the primary endpoint and found improvement, but it did not report detailed plasma NMN or NAD+ pharmacokinetic curves. Igarashi et al. (2022) randomized 42 healthy older men to 250 mg/day NMN versus placebo for 12 weeks, measuring blood NAD+ metabolites and muscle function. Irie et al. (2020) administered single doses of 100, 250, and 500 mg NMN to 10 healthy Japanese men and collected blood and urine samples over 5 hours, providing the most direct pharmacokinetic profile available for oral NMN in humans.

Liao et al. (2021) studied amateur runners with 300–1200 mg/day NMN for 6 weeks, focusing on aerobic capacity rather than pharmacokinetics. Niu et al. (2023) used 300 mg/day for 8 weeks in a pre-aging cohort and measured serum metabolites, fecal microbiota, and telomere length. Gomes et al. (2013) provided foundational mechanistic data in mice, demonstrating that declining NAD+ disrupts nuclear-mitochondrial communication via pseudohypoxia, but this is animal work and does not inform human pharmacokinetics directly.

The NR literature, while larger in trial count, suffers from similar limitations: different formulations (crystalline vs. amorphous), different doses, and inconsistent metabolite assays. No published trial has administered NMN and NR to the same participants under identical conditions and measured comparative plasma AUCs for NAD+ or the precursors themselves.

Study	Precursor	Dose	Duration	Population	Pharmacokinetic Data Reported
Irie et al. (2020)	NMN	100–500 mg (single dose)	Acute (5 h)	10 healthy Japanese men	Plasma NMN, NR, NAM curves; urinary metabolites
Yoshino et al. (2021)	NMN	250 mg/day	10 weeks	25 prediabetic women	None (insulin sensitivity primary outcome)
Igarashi et al. (2022)	NMN	250 mg/day	12 weeks	42 healthy older men	Blood NAD+ metabolites (chronic, not acute PK)
Liao et al. (2021)	NMN	300–1200 mg/day	6 weeks	48 amateur runners	None (aerobic capacity primary outcome)
Niu et al. (2023)	NMN	300 mg/day	8 weeks	20 pre-aging adults	Serum metabolomics (chronic, limited PK detail)

The Mechanism

Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are biosynthetic precursors to NAD+, the central redox cofactor and substrate for sirtuins, PARPs, and CD38. The body maintains NAD+ through the de novo pathway from tryptophan, the Preiss-Handler pathway from nicotinic acid, and the salvage pathway from nicotinamide (NAM) and its riboside derivatives. NMN and NR both feed into the salvage pathway, but at different enzymatic steps.

NR is a riboside of nicotinamide. Once inside a cell, NR is phosphorylated by nicotinamide riboside kinases (NRK1 and NRK2) to form NMN. NMN is then adenylylated by NMNAT1-3 to form NAD+. In theory, NMN bypasses the NRK step and enters the pathway one step downstream. Whether this confers a pharmacokinetic advantage depends on whether intact NMN can reach tissues without first being converted to NR or NAM in the gut, liver, or plasma.

Irie et al. (2020) found that oral NMN administration raised plasma NMN levels within 30 minutes, peaking around 60 minutes, with a secondary rise in plasma NR and NAM. This pattern suggests that at least some NMN is absorbed intact, but also that significant conversion to NR and NAM occurs—either at the intestinal mucosa, during first-pass hepatic metabolism, or in plasma. The appearance of NAM in plasma is particularly relevant because NAM can be methylated and excreted, representing a potential loss pathway if doses are excessive.

NR studies using labeled isotopes have shown that oral NR raises plasma NAD+ metabolites, but much of the labeled material appears as NAM rather than intact NR, suggesting extensive presystemic metabolism. Whether NMN avoids this more effectively than NR is biologically plausible but not yet proven in a direct comparison. The molecular weight difference is modest (NMN: 334.22 g/mol; NR: 255.25 g/mol), but NMN carries a phosphate group that may affect transporter affinity and membrane permeability.

Absorption Pathways and First-Pass Metabolism

The gut is not a passive conduit. Intestinal epithelial cells express CD73, which can dephosphorylate NMN to NR. They also express NRKs, which could phosphorylate NR back to NMN. This creates a dynamic equilibrium at the absorption surface that complicates any simple "NMN is absorbed intact" narrative. Irie et al. (2020) detected NR in plasma after NMN dosing, confirming that dephosphorylation occurs, but the relative contribution of intact NMN versus NMN-derived NR to tissue NAD+ pools remains unknown.

Hepatic first-pass metabolism adds another layer. The liver is a major site of NAD+ synthesis and consumption. High concentrations of NAM in portal blood can trigger methylation by nicotinamide N-methyltransferase, producing N-methylnicotinamide for renal excretion. This is a saturable pathway, meaning higher single doses may produce disproportionately more NAM excretion and less NAD+ retention. Chronic dosing, as in Yoshino et al. (2021) and Igarashi et al. (2022), may allow adaptive upregulation of salvage enzymes, but this has not been directly demonstrated in the available trials.

For consumers evaluating NMN absorption and bioavailability, the key takeaway is that absorption is rapid but not necessarily efficient in a single-dose context. Split dosing or sustained-release formulations may theoretically improve retention, though no human trial has tested this formally against immediate-release NMN.

What the Evidence Does Not Show

It is tempting to assume that because NMN is "closer" to NAD+ biochemically, it must raise tissue NAD+ more effectively than NR. This assumption is unsupported by direct human data. No study has measured skeletal muscle NAD+ content after equimolar NMN and NR doses in the same participants. The Yoshino et al. (2021) and Igarashi et al. (2022) trials used muscle biopsies with NMN, but no NR comparator was included.

Similarly, claims about NMN crossing cell membranes via specific transporters (such as the proposed Slc12a8 transporter identified in mouse intestine) have not been validated in human pharmacokinetic studies. The existence of a dedicated NMN transporter in humans remains speculative. Without transporter-specific pharmacokinetic data, arguments that NMN has superior cell permeability rest on preclinical inference, not clinical measurement.

Long-term safety data are also limited. The longest published human NMN trial is 12 weeks (Igarashi et al., 2022). NR has been studied for longer durations, but again, no head-to-head safety comparison exists. For anyone researching NMN vs NR in depth, the honest conclusion is that both compounds show promise and both lack definitive comparative pharmacokinetic validation.

Who Benefits Most

The populations with the strongest human evidence for NMN supplementation are narrowly defined. Yoshino et al. (2021) demonstrated improved muscle insulin sensitivity in postmenopausal women with prediabetes—a group with established metabolic dysfunction and likely reduced baseline NAD+ status. Igarashi et al. (2022) showed altered muscle function (improved gait speed and grip strength in some analyses) in healthy older men, suggesting that aging itself, even without overt disease, may create a responsive substrate.

Athletes have been studied by Liao et al. (2021), but the outcomes were mixed and dose-dependent, with higher doses (1200 mg/day) showing more consistent improvements in oxygen uptake than lower doses. The pre-aging cohort in Niu et al. (2023) showed metabolic and telomere length changes, but the sample was small and the clinical significance of telomere findings is debated.

There is no compelling human evidence that young, healthy, metabolically normal individuals benefit from either NMN or NR in terms of measurable performance or longevity outcomes. Gomes et al. (2013) established that NAD+ decline is mechanistically linked to aging in mice, but mouse aging is not human aging, and pharmacokinetic extrapolation across species is unreliable.

Practical Takeaways

• Dose conservatively based on existing trials. The human evidence for efficacy centers on 250–500 mg/day of NMN. Higher doses have been tested acutely (Irie et al., 2020) and in athletes (Liao et al., 2021), but the dose-response curve for NAD+ elevation has not been fully characterized.
• Expect rapid absorption but uncertain tissue delivery. Plasma NMN rises within 30–60 minutes of oral dosing, but how much reaches muscle, brain, or other target tissues as intact NMN versus metabolites is unknown.
• Do not assume NMN is universally superior to NR. The pharmacokinetic argument for NMN is plausible but unproven in direct human comparison. Both precursors likely converge on the same salvage pathway intermediates.
• Consider timing and formulation. Single large doses may saturate methylation pathways and increase NAM excretion. Split dosing or enteric formulations may improve retention, though human data are lacking.
• Monitor for individual response. Because pharmacokinetics vary with age, gut health, liver function, and genetics, personal biomarker tracking (if available) is more informative than following generic dosing advice.
• Choose verified products. Given the lack of regulatory standardization, third-party testing for purity and stated dose is essential. For those seeking a higher-dose option, Bio:sudo NMN 1000mg provides a tested formulation that aligns with the upper range of studied intakes, though individual needs should guide actual dosing.

Bottom Line

The pharmacokinetic case for NMN over NR rests on mechanistic plausibility and a small set of human trials showing rapid plasma appearance and metabolic effects in specific populations. It does not rest on direct comparative absorption data, which remains the critical missing piece. For now, the decision between NMN and NR is less about proven pharmacokinetic superiority and more about the quality of available evidence, product verification, and individual health context. Anyone evaluating the best NMN supplements for 2026 should prioritize transparency in sourcing and testing over marketing claims about "better" absorption that have not been clinically validated.

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging. 2022;8(1):5. [Source]
3. Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal. 2020;67(2):153–160. [Source]
4. Liao B, et al. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." Journal of the International Society of Sports Nutrition. 2021;18(1):54. [Source]
5. Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638. [Source]
6. Niu KM, et al. "The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase." Nutrients. 2023;15(3):755. [Source]

---

---